Trial · NCT01460160
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 3-year Event-free Survival (EFS) Rate | Dasatinib Cohort | 66.0 | 90% Confidence Interval 57.7 to 73.7 | Percentage of Participants | |
| Number of Participants Experiencing Adverse Events | Dasatinib Cohort | Adverse Events (AEs) | 106 | Participants | |
| Number of Participants Experiencing Adverse Events | Dasatinib Cohort | Drug-related AEs | 88 | Participants | |
| Number of Participants Experiencing Adverse Events | Dasatinib Cohort | AEs leading to discontinuation | 7 | Participants | |
| Number of Participants Experiencing Adverse Events | Dasatinib Cohort | Serious Adverse Events (SAEs) | 101 | Participants | |
| Number of Participants Experiencing Adverse Events | Dasatinib Cohort | Deaths | 15 | Participants | |
| Event-Free Survival (EFS) Rate (Kaplan-Meier Estimates) | Dasatinib Cohort | 3-year EFS Estimate | 65.5 | 95% Confidence Interval 55.5 to 73.7 | Percentage of Participants |
| Event-Free Survival (EFS) Rate (Kaplan-Meier Estimates) | Dasatinib Cohort | 5-year EFS Estimate | 53.1 | 95% Confidence Interval 42.8 to 62.3 | Percentage of Participants |
| Complete Remission Rate | Dasatinib Cohort | End of Induction period Ia | 65.1 | Percentage of Partcipants | |
| Complete Remission Rate | Dasatinib Cohort | End of Induction period Ib | 88.7 | Percentage of Partcipants | |
| Complete Remission Rate | Dasatinib Cohort | End of Consolidation period | 93.4 | Percentage of Partcipants | |
| Percentage of Participants Negative for Minimal Residual Disease (MRD) | Dasatinib Cohort | End of Induction period Ia | 28.3 | 95% Confidence Interval 19.98 to 37.88 | Percentage of Participants |
| Percentage of Participants Negative for Minimal Residual Disease (MRD) | Dasatinib Cohort | End of Induction period Ib | 52.8 | 95% Confidence Interval 42.89 to 62.60 | Percentage of Participants |
| Percentage of Participants Negative for Minimal Residual Disease (MRD) | Dasatinib Cohort | End of Consolidation period | 71.7 | 95% Confidence Interval 62.12 to 80.02 | Percentage of Participants |
| Percentage of Participants With BCR-ABL Mutations at Baseline and at Time of Disease Progression or Relapse | Dasatinib Cohort | At Baseline | 1.3 | Percentage of participants | |
| Percentage of Participants With BCR-ABL Mutations at Baseline and at Time of Disease Progression or Relapse | Dasatinib Cohort | At Disease Progression or Relapse | 6.5 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01460160/results